Transforming the Treatment of Hemorrhage

Cayuga Biotech is harnessing the body’s innate ability to stop bleeding with first-in-class therapeutics.

Life-threatening hemorrhage

Hemorrhage accounts for nearly 2 million deaths per year
Today’s treatments do not adequately treat noncompressible hemorrhage and many types of coagulation dysfunction, such as that due to Plavix® (clopidogrel), an irreversible platelet inhibitor.
This results in delayed hemostatic control. Every second counts and can make a difference for survival.
Hemorrhage is a top underlying cause of death after surgery, childbirth, trauma and related to the use of blood thinners.
With over 3.5 million annual treatment opportunities, the total addressable market size is $25B.

References: Cannon 2018, Eastridge et al 2019, Gimbel et al 2018, Kelly et al 2008, ClinCalc Drug Usage Statistics 2020

References: www.pathwaytocures.org, Okaygoun et al 2021

Cayuga was founded to address significant unmet need using proprietary science that enables us to tackle hemorrhage in a novel way.

References: Cannon 2019; Kelly et al 2008, Brohi et al 2019, Eastridge et al 2019, Clark et al 2002